To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.
This is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the treatment of LSCD with associated neurotrophic keratopathy. Patient diagnosed with LSCD with neurotrophic cornea who have failed conventional treatment such as artificial tears are enrolled in the study after a 2 week washout period. Patient are then treated with cenegermin-bkbj over an 8 week period.
Study Type
OBSERVATIONAL
Enrollment
5
Topical Cenegermin-bkbj 6 times per day for 8 weeks.
Stanford University
Stanford, California, United States
Size of abnormal epithelium
Change in size of abnormal epithelium compared to baseline
Time frame: Baseline, week 8
Number of patients with resolution of epithelial defect if present prior to treatment
Number of patients with resolution of epithelial defect if present prior to treatment (Stage 2) Mackie Classification of neurotrophic cornea at time of enrollment.
Time frame: Baseline, week 8
Cornea sensation
Cornea sensation measured with Cochet-Bonnet aesthesiometer after treatment compared to screening visit.
Time frame: Baseline, week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.